" ANP advises that further discussions with the
international pharmaceutical company on licensing of the ATL1103 will not proceed ahead of the Phase II clinical trial."
No surprise there of course as licensing something that is not proven would seem unusual.
Looks like it will break out of the 1.3 trading range but unsure which way
" ANP advises that further discussions with theinternational...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.8¢ |
Change
-0.003(3.70%) |
Mkt cap ! $82.67M | |||
| Open | High | Low | Value | Volume |
| 8.1¢ | 8.1¢ | 7.8¢ | $215.5K | 2.715M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 137820 | 7.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.0¢ | 319232 | 3 |
View Market Depth
| Last trade - 15.59pm 19/11/2024 (20 minute delay) ? |
| PER (ASX) Chart |